Jove
Visualize
お問い合わせ
JoVE
x logofacebook logolinkedin logoyoutube logo
JoVEについて
概要リーダーシップブログJoVEヘルプセンター
著者向け
出版プロセス編集委員会範囲と方針査読よくある質問投稿
図書館員向け
推薦の声購読アクセスリソース図書館諮問委員会よくある質問
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
利用規約
プライバシーポリシー
ポリシー

関連する概念動画

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Lineage Commitment01:21

Lineage Commitment

Commitment is the  process whereby stem cells:
Chronic Inflammation: Introduction01:12

Chronic Inflammation: Introduction

Chronic inflammation is a prolonged, dysregulated immune response that persists for weeks to years when the inciting stimulus is difficult to eradicate or when self‑antigens drive ongoing reactivity. Morphologically, it is defined by mononuclear cell infiltration, progressive tissue destruction, and concurrent attempts at healing via angiogenesis and fibrosis. Compared with acute inflammation, edema is less prominent while cellular infiltration predominates; triggers include persistent...

こちらも読む

関連記事

共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

並び替え
Same author

Long read nanopore DNA sequencing with adaptive sampling to identify tyrosine kinase fusion genes.

Leukemia·2025
Same author

Differential prognostic impact of myelodysplasia-related gene mutations in a European cohort of 4978 intensively treated AML patients.

Leukemia·2025
Same author

Liver transplantation in well-selected patients with unresectable colorectal liver metastases.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2025
Same author

Are real world data real world data?

Leukemia·2025
Same author

Combined heterozygosity for the highly unstable variant hemoglobin Taybe, and α-thalassemia as a rare cause of hemolytic anemia.

Annals of hematology·2025
Same author

Venetoclax in combination with ponatinib for the treatment of asciminib-resistant chronic myeloid leukemia.

Leukemia·2025

関連する実験動画

Updated: Jul 13, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

慢性骨髄性白血病 慢性骨髄性白血病 慢性骨髄性白血病 慢性骨髄性白血病 慢性骨髄性白血病 慢性骨髄性白血病 慢性骨髄性白血病 慢性骨髄性白血病

Rüdiger Hehlmann1, Andreas Hochhaus, Michele Baccarani

  • 1III Medizinische Universitätsklinik, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany. Ruediger.Hehlmann@med3.ma.uni-heidelberg.de

Lancet (London, England)
|July 31, 2007
PubMed
まとめ

慢性骨髄性白血病 (CML) は,明確な原因と標的治療により,モデルがんである. イマチニブはCML治療に革命を起こし,高い寛解率と新しい治療法の進行中の研究をもたらしました.

さらに関連する動画

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

関連する実験動画

Last Updated: Jul 13, 2026

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up
09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia
09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

科学分野:

  • 腫瘍学 腫瘍学
  • 血液学 ヘマトロジ
  • ファルマコゲノミクスとは

背景:

  • 慢性骨髄性白血病 (CML) は,よく理解されている病理生理学を持つ腫瘍性疾患です.
  • その遺伝的基礎 (BCR-ABL融合遺伝子) は,標的治療の開発を可能にしました.
  • CMLは,遺伝子型主導のがん治療のパラダイムとして機能しています.

研究 の 目的:

  • 慢性段階のCMLの現在の管理を見直す.
  • CML患者における疾患状態のモニタリングに関するガイドラインを提供すること.
  • CMLのアウトカムに対する標的治療の影響を強調する.

主な方法:

  • CMLの病理生理学,診断,治療に関する文献レビュー.
  • 治療ガイドラインと臨床試験の結果の分析.
  • 完全な細胞遺伝的寛解を達成するためのモニタリング戦略の議論.

主要な成果:

  • BCR-ABLチロシンキナーゼ阻害剤であるイマチニブは,慢性期CMLの標準的な第一線治療である.
  • イマチニブを使用すると,完全な細胞遺伝性寛解の高い割合 (最大87%) が達成できます.
  • 代替治療には,アルファインターフェロン,幹細胞移植,用量エスカレーション,または治療が失敗した場合の新薬が含まれます.

結論:

  • イマチニブはCMLの管理に変革をもたらし,高い有効性と改善された患者のアウトカムを提供しました.
  • 治療への反応を評価し,CMLの管理を行うには,密接なモニタリングが不可欠です.
  • 進行中の研究は,CML治療をさらに強化するために新しい薬剤と組み合わせ治療法を調査しています.